by Annabel Sedgwick
Share
by Annabel Sedgwick
Share
June Medical is one of 48 organisations to be recognised for their excellence in innovation in this year’s Queen’s Awards for Enterprise. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country – rewarding only the most outstanding achievements – with winning businesses able to use the esteemed Queen’s Awards emblem for the next five years.
June Medical is a medical device company with a global reach, and already has multiple highly regarded accolades to its name. Based in High Wycombe, UK, it continues to lead from the front by delivering medical innovations to address unmet surgical needs – adding lasting value to the medical community. The company’s Galaxy II single-use surgical retractor reduces the need for extra staff during surgery, and lowers the risk of patient-to-patient cross-contamination. The ground-breaking product has been well received by surgeons across the UK and internationally, and its widespread success has earned June Medical this prestigious award.
Angela Spang, CEO and founder of June Medical, pioneered the Galaxy II range and is delighted with the honour the company has received. She commented: “This award is the result of all the hard work from everyone in the team. Our vision is to positively impact patients’ lives by making surgery easier for the surgeons and nurses, and safer for every patient. Being recognised today for our work will help the company continue this quest.”
Read more on The Queen’s Awards for Enterprise here
To find out more about JUNE Medical, visit junemedical.com
About JUNE Medical Group
JUNE Medical Group is an award-winning medical device company with offices in the UK, USA and Sweden. JUNE Medical represents selected products from leading manufacturers, with the flagship product being the innovative and popular Galaxy II self-retaining retractor.
Microban® International – the global leader in antimicrobial additives and odor control solutions – has released a statement discrediting unwarranted claims about the safety and efficacy of antimicrobial technologies. This statement is intended to ensure that the public, consumers, and other stakeholders are equipped to make fully informed decisions, based on scientific reasoning. Making a clear distinction between public health and non-public health claims, Microban has explained the advantages of incorporating its antimicrobial additives into
Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyze the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell
A report from the International Agency for Research on Cancer1 recently classified TiO2 as ‘possibly carcinogenic to humans’ by inhalation and similarly, the European Chemicals Agency2 recommended TiO2 be classified as a category 2 carcinogen (suspected of causing cancer). In contrast, antimicrobial technologies from Microban International are based on SilverShield®, the first patented antimicrobial solution
INTEGRA Biosciences’ VIAFLO electronic pipettes are helping denovoMATRIX in Dresden, Germany, to produce modular, biomimetic coatings for cell culture plasticware that can be tailored to recreate a large variety of conditions for testing adherent cell cultures. Chief Scientific Officer Dr Richard Wetzel explained: “We have developed a range of pre-coated cell culture plasticware – screenMATRIX and myMATRIX – and